The company's lead gene therapy candidate, D-Fi, is in late-stage clinical testing as a potential treatment of recessive dystrophic epidermolysis ...
https://www.google.com/url?rct=j&sa=t&url=https://www.bizjournals.com/philadelphia/news/2021/12/30/castle-creek-biosciences-ipo-exton-cell-gene-rdeb.html&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNEyvT4YWwNMobCNfZ4JdVqk7R7N-w
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.